Venkat K. Rao

Management of gestational gigantomastia.

Background: Gigantomastia of pregnancy is a rare, severely debilitating condition characterized by massive enlargement of breasts and resulting in tissue necrosis, ulceration, infection, and, occasionally, hemorrhage. Typically, resolution of breast hypertrophy to near prepregnancy size occurs in the postpartum period. Treatment is controversial. Methods: The authors present a patient with gestational gigantomastia for whom nonoperative management failed and who subsequently required bilateral mastectomies. In addition, the authors performed a comprehensive review of reported cases and generated a treatment algorithm. Results: The patient tolerated the mastectomies well and went on to deliver a healthy child. Postpartum delayed breast reconstruction with tissue expansion and implant placement yielded good results. The literature review demonstrates that medical management has successfully avoided surgery during gestation in 39 percent of cases since 1968. However, 35 percent of patients eventually underwent breast reduction (12 percent) or mastectomy (88 percent) during pregnancy. Spontaneous or elective termination of the pregnancy accounted for 30 percent of outcomes. Patients who underwent breast reduction and then became pregnant had a 100 percent (four of four patients) chance of recurrence. Two women had mastectomy and subsequent pregnancies. One woman developed multiple small areas of recurrence that were surgically excised. The other woman had two additional pregnancies with no recurrence of symptoms. Conclusions: Medical therapies to manage gestational gigantomastia are inconsistent in outcome. Since some patients respond, these therapies are worth trying. However, if the patient and/or fetus are experiencing significant morbidity, then surgical intervention is warranted. Breast reduction or mastectomy with delayed reconstruction is the preferred procedure. If the mother is considering future pregnancies, mastectomy offers the lowest risk of recurrence.

Glomus tumor of the index finger.

A 41-year-old female patient presented with localized worsening subungual pain of her right index finger. Subsequent diagnostic evaluation revealed the presence of a glomus tumor. A glomus tumor is a rare tumor with a predilection for the hand. Classic symptoms include pain, pain with pressure, and pain with cold temperature. We present a completely updated literature review that addresses the epidemiology, pathology, presentation, diagnostic evaluation, classification, histology, genetics, and treatment options for glomus tumors.

Intraoral reconstruction with a microvascular peritoneal flap

The microvascular peritoneal flap offers a new reconstructive option for closure of intraoral defects. The flap is easy to raise, and donor-site morbidity is low. Unlike fascial flaps, in which the raw surface may take weeks to “mucosalize,” the peritoneal surface heals primarily. Finally, the rectus muscle effectively covers all forms of mandibular reconstruction, and the reliable skin paddle makes possible the closure of substantial cutaneous defects.

Improved preservation of rat hindlimbs with the University of Wisconsin solution and butanedione monoxime.

&NA; The purpose of this study was to compare the effects of the University of Wisconsin solution plus butanedione monoxime, the University of Wisconsin solution without butanedione monoxime, and saline on the preservation of muscle tissue. Forty‐nine rat hindlimbs were amputated and replanted. The study population was subdivided into four groups according to flushing solution, storage, and replantation protocols. The limbs of the control group (n = 12) were flushed with 20 ml University of Wisconsin solution and immediately replanted onto the same rat. In the remaining three groups, the limbs were immersed in solution, stored in a refrigerator at 4°C for 24 hours, and then replanted onto a fresh rat. The limbs in the no flushout group (n = 7) were placed into storage in cold saline solution without being flushed. The limbs in the University of Wisconsin solution group (n = 17) were flushed with 20 ml of University of Wisconsin solution prior to storage, and those in the University of Wisconsin solution plus butanedione monoxime group (n = 13) were flushed with 20 ml University of Wisconsin solution plus 20 mM butanedione monoxime. Limb survival rate was 100 percent for the control and University of Wisconsin solution plus butanedione monoxime groups, 87 percent for the University of Wisconsin solution group, and 71 percent for the no flushout group. Seven days after replantation, ATP levels were 71 percent of control in the University of Wisconsin solution plus butanedione monoxime group, 33 percent in the University of Wisconsin solution group, and 29 percent in the no flushout group. Tissue K+/Na+ ratio showed that the University of Wisconsin solution plus butanedione monoxime group maintained electrolyte balance, whereas the balance was significantly lowered in University of Wisconsin solution and no flushout groups. The University of Wisconsin solution plus butanedione monoxime limbs did not exhibit cell swelling, whereas total tissue water values for the University of Wisconsin solution and no flushout groups increased significantly. Serum creatinine kinase, measured 24 hours after replantation, was 120 percent of control in the University of Wisconsin solution plus butanedione monoxime group, 550 percent in the University of Wisconsin solution group, and 772 percent in the no flushout group. Limbs in the University of Wisconsin solution plus butanedione monoxime group had more flexible ankle joints and pliable muscle (i.e., less contracture) than those in the University of Wisconsin solution and no flushout groups. In conclusion, rat hindlimbs can be preserved hypothermically for 24 hours using the University of Wisconsin solution, the University of Wisconsin solution plus butanedione monoxime, or saline. However, the University of Wisconsin solution plus butanedione monoxime limbs had better ATP levels and less cellular injury after replantation. Based on these results, we believe that, biochemically, flushing and storage of muscle tissue in the University of Wisconsin solution plus butanedione monoxime are the most effective means of those studied for preserving composite tissue grafts for 24 hours. (Plast. Reconstr. Surg. 100: 957, 1997.)

The Economics of Skin Cancer: An Analysis of Medicare Payment Data.

Purpose: The incidence and cost of nonmelanoma skin cancers are skyrocketing. Five million cases cost

The Affordable Care Act: a primer for plastic surgeons.

8.1 billion in 2011. The average cost of treatment per patient increased from

Soft Tissue Reconstruction and Flap Coverage for Revision Total Knee Arthroplasty.

1000 in 2006 to

Plastic Surgeons’ Perceptions of the Affordable Care Act: Results of a National Survey

1600 in 2011. We present a study of the economics and costs of skin cancer management in Medicare patients. Methods: We studied data released by the Centers for Medicare and Medicaid Services in 2014. Treatment modalities for the management of skin cancer were reviewed, and costs of treatment were quantified for a sample of 880,000 providers. Results: Review of Medicare payment records related to the management of skin cancer yielded data from over 880,000 health care providers who received

Establishing a multidisciplinary academic cosmetic center.

77 billion in Medicare payments in 2012. From 1992 to 2009, the rate of Mohs micrographic surgery (MMS) has increased by 700%, and these procedures typically have Medicare payments 120% to 370% more than surgical excision, even when including pathology fees. From 1992 to 2009, MMS increased by 700%, whereas surgical excisions increased by only 20%. In 2009, 1800 providers billed Medicare for MMS; in 2012, that number increased to 3209. On average, 1 in 4 cases of skin cancer is treated with MMS. Conclusion: Mohs excision is more expensive than surgical excision in an office setting. Procedures requiring the operating room are much more expensive than office procedures. In an era of high deductible health plans, patients’ financial burden is much less with simple excisions of skin cancers done in a clinic when compared with Mohs surgery or operative interventions.

Systematic Review and Operative Technique of Recalcitrant Pressure Ulcers Using a Fillet Flap Technique.

Summary: The Patient Protection and Affordable Care Act, sometimes referred to as Obamacare, was signed into law on March 23, 2010. It represents the most extensive overhaul of the country’s health care system since the passage of Medicare and Medicaid in 1965. The Affordable Care Act has two goals. The first goal is to reduce the uninsured population in the United States. Key elements to covering the uninsured include the following: (1) expanding Medicaid coverage for low-income individuals and (2) establishing health insurance marketplaces for moderate-income individuals with subsidies and tax cuts in an effort to make health insurance more affordable. The second goal of the Affordable Care Act is to address concerns about quality and the overall cost of U.S. health care. It is imperative that plastic surgeons thoroughly understand the impact that the Affordable Care Act will undoubtedly have on the country, on our patients, and on our clinical practices. Plastic surgery will see many changes in the future. This will include an overall increase in the number of insured patients, a push toward joining accountable care organizations, and a shift in payment systems to bundled reimbursement for episodes of care. In this article, the authors describe how these changes are likely to occur and what plastic surgeons must do to be part of the change.